S&P 500
$5,818.73
-0.4%
-$23.28
DJI
$41,714.90
-0.3%
-$144.19
NASDAQ
$18,808.88
-0.6%
-$116.85
Bitcoin
109,291.00
-1.8%
-2,059.26
AAPL
$196.38
-2.5%
-$4.98
AMZN
$201.90
-0.6%
-$1.20
GOOG
$171.03
-0.6%
-$0.95
META
$632.01
-0.7%
-$4.56
MSFT
$452.52
-0.5%
-$2.34
NVDA
$131.74
-0.8%
-$1.09
TSLA
$341.99
+0.3%
+$0.95
Immunic (NASDAQ: IMUX)
$0.90
(-2.1%)
-$0.02
Price as of May 23, 2025, 1:02 p.m. ET
Immunic Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Immunic Company Info
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The firm’s products include IMU-838, IMU-935, and IMU-856. The company is headquartered in New York, NY.
News & Analysis
Featured Article
Why Immunic Plummeted by 21% on Thursday
Word of a new share issue made investors feel queasy.
Eric Volkman | Jul 15, 2021
Featured Article
Why Immunic Stock Is Soaring Today
An analyst says buy.
Prosper Junior Bakiny | Aug 26, 2020
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.